Print

Miravant's (MRVT) Photrex -- SnET2 -- Presented At American Academy of Ophthalmology 
10/19/2005 5:11:55 PM

Miravant Medical Technologies (OTCBB:MRVT), a pharmaceutical development company specializing in PhotoPoint(TM) photodynamic therapy (PDT), announced today additional results from analyses of the Photrex(TM) (rostaporfin, SnET2) phase III clinical trials, presented at the American Academy of Ophthalmology (AAO) meeting, New Orleans. Photrex is a proprietary PDT drug in development for the treatment of wet age-related macular degeneration (AMD), a leading cause of blindness in older adults. Based on data from two randomized, placebo controlled two-year trials, clinical investigators reported on: